Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 17, 2022, InVivo Therapeutics Holdings Corp. (the "Company") entered into an amendment to the existing employment agreement dated December 24, 2018 (the "Employment Agreement") with Richard Christopher, the Company's Chief Financial Officer (the "Amendment"). The Amendment provides for an increase from six (6) to twelve (12) months of continuation of Mr. Christopher's health insurance benefits under the Company's employee group health insurance plan from the date of termination in the event Mr. Christopher's employment is terminated by the Company without Cause or if he terminates his employment for Good Reason (each as defined in the Employment Agreement), in each case prior to, or more than 12 months following, a Change in Control (as defined in the Employment Agreement), unless Mr. Christopher becomes eligible for coverage under a new employer group's health plan.

The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed herewith as Exhibit 10.1, and is incorporated by reference herein. Unless otherwise specified, capitalized terms used above without definition have the meanings set forth in the Employment Agreement or the Amendment.





                                       2


Item 9.01    Financial Statements and Exhibits.



(d)    Exhibits



Exhibit
Number                                  Description

  10.1       Amendment to Employment Agreement, by and between InVivo
           Therapeutics Holdings Corp. and Richard Christopher, dated
           November 17, 2022.

104        Cover Page Interactive Data File - the cover page iXBRL tags are
           embedded within the inline XBRL document.




                                       3

© Edgar Online, source Glimpses